Antonio Ahn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Antonio Ahn has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Alec Trub
Incyclix Bio, Durham, North Carolina
27 shared publications - April C. Watt
Peter MacCallum Cancer Centre, Melbourne, Australia
27 shared publications Catherine Blyth
27 shared publications- Catherine Dietrich
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
27 shared publications - Christabella A. Mahendra
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
27 shared publications - Jay Strum
Incyclix Bio, Durham, North Carolina
27 shared publications
Latest Publications
- Open Access
- 29 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
LanthaScreen Eu Kinase Binding and Z’-Lyte Kinase Assay data for INX-315
- 29 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
LanthaScreen Eu Kinase Binding and Z’-Lyte Kinase Assay data for INX-315
- Open Access
- 29 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Experimental conditions for Nanosyn assays
- 29 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Experimental conditions for Nanosyn assays
- Open Access
- 29 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Description of methods to synthesize INX-315
- 29 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Description of methods to synthesize INX-315
- Open Access
- 29 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Figure 1: Characterization of INX-315.Supplementary Figure 2: Effect of INX-315 and PF-07104091 on viability of cancer and non-malignant cell lines.Supplementary Figure 3: Effect of INX-315 on cell cycle in CCNE1-amplified cancer cell lines.Supplementary Figure 4: Further characterization of the effects of INX-315 in in vitro and in vivo models of CCNE1-amplified cancer.Supplementary Figure 5: Effects of INX-315 treatment on gene expression in models of CCNE1amplified ovarian carcinoma.Supplementary Figure 6: Characterization of CDK4/6 inhibitor-resistant cell lines.Supplementary Figure 7: Response of CDK4/6 inhibitor-resistant breast cancer cells to INX-315 and PF-07104091.Supplementary Figure 8: Effects of INX-315 and PF-07104091 on CDK4/6 inhibitor-resistant breast cancer cells.Supplementary Figure 9: Impact of INX-315 +/- continued CDK4/6 inhibition in CDK4/6 inhibitorresistant breast cancer cells.Supplementary Figure 10: Characterization of a new mouse model of acquired CDK4/6 inhibitor resistance.Supplementary Figure 11: Effect of INX-315 on expression of senescence-related genes in CDK4/6 inhibitor-resistant breast cancer cells.Supplementary Figure 12: Epigenomic and transcriptomic features of INX-315 induced senescence in CDK4/6 inhibitor-resistant breast cancer.Supplementary Figure 13: Impact of INX-315 treatment of CDK4/6 inhibitor resistant breast cancer on expression of apoptosis and differentiation-related genes.Supplementary Figure 14: Impact of co-inhibition of CDK2 and CDK4/6 on cell cycle and development of CDK4/6 inhibitor resistance in breast cancer cells.
- 29 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Figure 1: Characterization of INX-315.Supplementary Figure 2: Effect of INX-315 and PF-07104091 on viability of cancer and non-malignant cell lines.Supplementary Figure 3: Effect of INX-315 on cell cycle in CCNE1-amplified cancer cell lines.Supplementary Figure 4: Further characterization of the effects of INX-315 in in vitro and in vivo models of CCNE1-amplified cancer.Supplementary Figure 5: Effects of INX-315 treatment on gene expression in models of CCNE1amplified ovarian carcinoma.Supplementary Figure 6: Characterization of CDK4/6 inhibitor-resistant cell lines.Supplementary Figure 7: Response of CDK4/6 inhibitor-resistant breast cancer cells to INX-315 and PF-07104091.Supplementary Figure 8: Effects of INX-315 and PF-07104091 on CDK4/6 inhibitor-resistant breast cancer cells.Supplementary Figure 9: Impact of INX-315 +/- continued CDK4/6 inhibition in CDK4/6 inhibitorresistant breast cancer cells.Supplementary Figure 10: Characterization of a new mouse model of acquired CDK4/6 inhibitor resistance.Supplementary Figure 11: Effect of INX-315 on expression of senescence-related genes in CDK4/6 inhibitor-resistant breast cancer cells.Supplementary Figure 12: Epigenomic and transcriptomic features of INX-315 induced senescence in CDK4/6 inhibitor-resistant breast cancer.Supplementary Figure 13: Impact of INX-315 treatment of CDK4/6 inhibitor resistant breast cancer on expression of apoptosis and differentiation-related genes.Supplementary Figure 14: Impact of co-inhibition of CDK2 and CDK4/6 on cell cycle and development of CDK4/6 inhibitor resistance in breast cancer cells.
- Open Access
- 29 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Discovery and characterization of INX-315. A, Amino acid sequence homology at the ATP-binding pockets of several CDKs. B, Derivation of INX-315 through serial modifications of trilaciclib, a CDK4/6i. Table indicates biochemical IC50s (± SEM) to cyclin/CDK pairings shown using the Nanosyn biochemical assay. Trilaciclib IC50 for CDK1/cyclin B1 was ND (for trilaciclib: n = 6 for CDK2/cyclin E1 and CDK2/cyclin A2, n = 9 for CDK4/cyclin D1, n = 3 for other complexes; for compound B: n = 3 for all complexes; for compound C: n = 1 for all complexes; for INX-315: if SEM is 0, n = 1, otherwise n = 6). C, Modeling of INX-315 bound to cyclin E1/CDK2. D, NanoBRET assay quantifying INX-315's intracellular displacement of tracer from the ATP-pocket of the cyclin/CDK pairings shown. Table shows calculated IC50s (two technical replicates per experiment, two biological replicates except for CDK2/Cyclin A1 where n = 1; error bars represent SD).BID, twice daily; QD, once daily.
- 29 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Discovery and characterization of INX-315. A, Amino acid sequence homology at the ATP-binding pockets of several CDKs. B, Derivation of INX-315 through serial modifications of trilaciclib, a CDK4/6i. Table indicates biochemical IC50s (± SEM) to cyclin/CDK pairings shown using the Nanosyn biochemical assay. Trilaciclib IC50 for CDK1/cyclin B1 was ND (for trilaciclib: n = 6 for CDK2/cyclin E1 and CDK2/cyclin A2, n = 9 for CDK4/cyclin D1, n = 3 for other complexes; for compound B: n = 3 for all complexes; for compound C: n = 1 for all complexes; for INX-315: if SEM is 0, n = 1, otherwise n = 6). C, Modeling of INX-315 bound to cyclin E1/CDK2. D, NanoBRET assay quantifying INX-315's intracellular displacement of tracer from the ATP-pocket of the cyclin/CDK pairings shown. Table shows calculated IC50s (two technical replicates per experiment, two biological replicates except for CDK2/Cyclin A1 where n = 1; error bars represent SD).BID, twice daily; QD, once daily.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Figure 5 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
INX-315 treatment of CDK4/6i–resistant breast cancer reinstates a senescence phenotype. A, Representative images (top) and quantification (bottom) of staining MCF7 and T47D cells for beta-galactosidase activity after treatment with agents shown (500 nmol/L abemaciclib, INX-315: 300 nmol/L for MCF7 and 100 nmol/L for T47D) for 7 days (scale bar = 100 µm). Resistant cells were cultured continuously in drugs to which they were resistant (500 nmol/L abemaciclib ± 100 nmol/L fulvestrant). Experiments performed with three technical replicates. Quantification is for integrated beta-galactosidase signal per cell. Dashed line indicates cutoff used to define beta-galactosidase positivity. B, Representative images (top) and quantification of nuclear size (bottom) upon staining MCF7 and T47D cells with DAPI and phalloidin after treatment as in A (scale bar = 100 µm). Experiments performed with three technical replicates. C, Heat map shows z-scores for ssGSEA scores for four senescence-associated gene signatures, calculated from RNA-sequencing of MCF7 and T47D cells treated as in A. Bar plot above shows mean z-score for each sample across all signatures. Three technical replicates for all conditions except abemaciclib-resistant MCF7 in abemaciclib, which had two technical replicates. D, Heat map as in C, but for RNA-sequencing from abemaciclib-resistant MMTV-rtTA/tetO-HER2 tumors treated as in Fig. 4E. Six samples for vehicle and INX-315, five samples for abemaciclib and combination. E, Violin plots showing log2-transformed normalized ATAC-seq counts for genomic regions that significantly increased chromatin accessibility after abemaciclib treatment of parental cells. Cells treated as in A, two technical replicates. F, Scatter plots showing significant enrichment of AP-1 motifs in the ATAC-seq up peaks after treatment with drugs as in A. G, Heat map showing z-scores for individual SASP genes (RNA-sequencing) in MCF7 cells treated as in A. Bar plot above shows mean z-score for all genes in each sample. Three technical replicates for all conditions except abemaciclib-resistant MCF7 in abemaciclib, which had two technical replicates. H, Representative ATAC-seq tracks at regions near SASP genes (IGFBP3 and VEGFA) in cells treated as in A (all P values calculated using unpaired t tests except F, determined using HOMER package).
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
INX-315 treatment of CDK4/6i–resistant breast cancer reinstates a senescence phenotype. A, Representative images (top) and quantification (bottom) of staining MCF7 and T47D cells for beta-galactosidase activity after treatment with agents shown (500 nmol/L abemaciclib, INX-315: 300 nmol/L for MCF7 and 100 nmol/L for T47D) for 7 days (scale bar = 100 µm). Resistant cells were cultured continuously in drugs to which they were resistant (500 nmol/L abemaciclib ± 100 nmol/L fulvestrant). Experiments performed with three technical replicates. Quantification is for integrated beta-galactosidase signal per cell. Dashed line indicates cutoff used to define beta-galactosidase positivity. B, Representative images (top) and quantification of nuclear size (bottom) upon staining MCF7 and T47D cells with DAPI and phalloidin after treatment as in A (scale bar = 100 µm). Experiments performed with three technical replicates. C, Heat map shows z-scores for ssGSEA scores for four senescence-associated gene signatures, calculated from RNA-sequencing of MCF7 and T47D cells treated as in A. Bar plot above shows mean z-score for each sample across all signatures. Three technical replicates for all conditions except abemaciclib-resistant MCF7 in abemaciclib, which had two technical replicates. D, Heat map as in C, but for RNA-sequencing from abemaciclib-resistant MMTV-rtTA/tetO-HER2 tumors treated as in Fig. 4E. Six samples for vehicle and INX-315, five samples for abemaciclib and combination. E, Violin plots showing log2-transformed normalized ATAC-seq counts for genomic regions that significantly increased chromatin accessibility after abemaciclib treatment of parental cells. Cells treated as in A, two technical replicates. F, Scatter plots showing significant enrichment of AP-1 motifs in the ATAC-seq up peaks after treatment with drugs as in A. G, Heat map showing z-scores for individual SASP genes (RNA-sequencing) in MCF7 cells treated as in A. Bar plot above shows mean z-score for all genes in each sample. Three technical replicates for all conditions except abemaciclib-resistant MCF7 in abemaciclib, which had two technical replicates. H, Representative ATAC-seq tracks at regions near SASP genes (IGFBP3 and VEGFA) in cells treated as in A (all P values calculated using unpaired t tests except F, determined using HOMER package).
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Figure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Activity of INX-315 in CCNE1-amplified cancers. A, IC50s for palbociclib and INX-315 for cell lines shown using CellTiter Glo viability assay. All cells were treated for 6 days, n = 3 technical replicates per cell line. B, Cell cycle phase profiles of OVCAR-3 and MKN1 cells treated with INX-315. All cells were treated for 24 hours, n = 3 technical replicates per cell line; error bars are SD. C, Western blots for phosphorylated/total Rb and cyclin A2 in OVCAR3 and MKN1 cells treated with INX-315 for 24 hours. D and E, Tumor growth curves for CCNE1-amplified gastric and ovarian carcinoma models treated with INX-315 at doses shown (GA0103 n = 8 per group; GA0114 n = 8 per group; OVCAR3 n = 10 per group; OV5398 n = 10 per group; error bars represent SEM; P values calculated using two-way ANOVA. all experiments performed once). F, Western blots for phosphorylated/total Rb and cyclin A2 in tumor tissue lysates treated with control vehicle or INX-315. Samples were collected at experimental endpoint from experiments in E.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Activity of INX-315 in CCNE1-amplified cancers. A, IC50s for palbociclib and INX-315 for cell lines shown using CellTiter Glo viability assay. All cells were treated for 6 days, n = 3 technical replicates per cell line. B, Cell cycle phase profiles of OVCAR-3 and MKN1 cells treated with INX-315. All cells were treated for 24 hours, n = 3 technical replicates per cell line; error bars are SD. C, Western blots for phosphorylated/total Rb and cyclin A2 in OVCAR3 and MKN1 cells treated with INX-315 for 24 hours. D and E, Tumor growth curves for CCNE1-amplified gastric and ovarian carcinoma models treated with INX-315 at doses shown (GA0103 n = 8 per group; GA0114 n = 8 per group; OVCAR3 n = 10 per group; OV5398 n = 10 per group; error bars represent SEM; P values calculated using two-way ANOVA. all experiments performed once). F, Western blots for phosphorylated/total Rb and cyclin A2 in tumor tissue lysates treated with control vehicle or INX-315. Samples were collected at experimental endpoint from experiments in E.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
LanthaScreen Eu Kinase Binding and Z’-Lyte Kinase Assay data for INX-315
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
LanthaScreen Eu Kinase Binding and Z’-Lyte Kinase Assay data for INX-315
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Figure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Activity of INX-315 in CCNE1-amplified cancers. A, IC50s for palbociclib and INX-315 for cell lines shown using CellTiter Glo viability assay. All cells were treated for 6 days, n = 3 technical replicates per cell line. B, Cell cycle phase profiles of OVCAR-3 and MKN1 cells treated with INX-315. All cells were treated for 24 hours, n = 3 technical replicates per cell line; error bars are SD. C, Western blots for phosphorylated/total Rb and cyclin A2 in OVCAR3 and MKN1 cells treated with INX-315 for 24 hours. D and E, Tumor growth curves for CCNE1-amplified gastric and ovarian carcinoma models treated with INX-315 at doses shown (GA0103 n = 8 per group; GA0114 n = 8 per group; OVCAR3 n = 10 per group; OV5398 n = 10 per group; error bars represent SEM; P values calculated using two-way ANOVA. all experiments performed once). F, Western blots for phosphorylated/total Rb and cyclin A2 in tumor tissue lysates treated with control vehicle or INX-315. Samples were collected at experimental endpoint from experiments in E.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Activity of INX-315 in CCNE1-amplified cancers. A, IC50s for palbociclib and INX-315 for cell lines shown using CellTiter Glo viability assay. All cells were treated for 6 days, n = 3 technical replicates per cell line. B, Cell cycle phase profiles of OVCAR-3 and MKN1 cells treated with INX-315. All cells were treated for 24 hours, n = 3 technical replicates per cell line; error bars are SD. C, Western blots for phosphorylated/total Rb and cyclin A2 in OVCAR3 and MKN1 cells treated with INX-315 for 24 hours. D and E, Tumor growth curves for CCNE1-amplified gastric and ovarian carcinoma models treated with INX-315 at doses shown (GA0103 n = 8 per group; GA0114 n = 8 per group; OVCAR3 n = 10 per group; OV5398 n = 10 per group; error bars represent SEM; P values calculated using two-way ANOVA. all experiments performed once). F, Western blots for phosphorylated/total Rb and cyclin A2 in tumor tissue lysates treated with control vehicle or INX-315. Samples were collected at experimental endpoint from experiments in E.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Description of methods to synthesize INX-315
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Description of methods to synthesize INX-315